Skip to main content

Fangzhou and Cutia Therapeutics Partner to Advance AI-Powered Dermatology and Chronic Health Management

Written by Customer Service on . Posted in Public Companies.

GUANGZHOU, China, Oct. 19, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced a strategic partnership with Cutia Therapeutics (“Cutia”) at its 2026 Double 11 (Single’s Day) Partner Conference in Guangzhou, focused on integrating innovative dermatology treatments with AI-enabled, full-cycle health management services.

The conference, themed “AI Innovation for Efficiency, Data Services for Empowerment,” brought together industry experts, pharmaceutical partners and healthcare professionals to explore data-driven healthcare innovation.

Fangzhou and Cutia Partner to Advance AI-Powered Dermatology and Chronic Health Management

Fangzhou and Cutia Partner to Advance AI-Powered Dermatology and Chronic Health Management

The partnership will focus on integrating pharmaceutical product portfolios and AI-powered digital marketing, combining Cutia’s dermatology expertise with Fangzhou’s digital healthcare capabilities to accelerate access to innovative treatments and develop personalized, long-term patient management services.

Cutia Therapeutics specializes in dermatology and hair-related conditions, with broad capabilities spanning drug development, manufacturing and commercialization.

Fangzhou has continued to expand its “AI + Chronic Disease Services” model, supported by its proprietary “XingShi” Large Language Model (“XS LLM”). Its AI applications cover health monitoring, patient follow-up and health education, helping connect medical treatments with continuous healthcare services beyond individual consultations.

Wang Haijiao, Executive Director and Chief Executive Officer of Fangzhou, said, “China has a vast patient population and more diverse healthcare needs, creating significant opportunities for localized innovation. By leveraging Fangzhou’s established AI-powered healthcare capabilities, we aim to develop full-cycle management packages tailored to Chinese patients, integrating products, one-on-one follow-up, online assessments and health guidance into a comprehensive service model.”

Zhang Lele, Executive Director and Chief Executive Officer of Cutia Therapeutics, emphasized the substantial unmet clinical needs in dermatological healthcare. She expressed confidence that Fangzhou’s AI technology and digital service capabilities will help bridge the gap between innovative treatments and patients, expanding access to structured, high-quality and continuous health management.

Looking ahead, Fangzhou will continue to strengthen collaboration across the pharmaceutical and healthcare industries, expanding the application of AI in chronic disease services and developing integrated digital healthcare solutions to support the objectives of the Healthy China initiative.

About Fangzhou Inc.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 59.8 million registered users and 282,000 physicians (as of June 30, 2026). The Company specializes in delivering tailored medical care and AI‑enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact

For further inquiries or interview requests, please contact:

Xingwei Zhao
Director of Public Relations
Email: pr@jianke.com

Disclaimer: This press release contains forward‑looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/92b944d6-36c5-4b26-91bb-a3347906e430

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.